The Westaim Co. (CVE:WED – Free Report) – Stock analysts at Cormark issued their Q1 2025 earnings per share (EPS) estimates for shares of Westaim in a note issued to investors on Wednesday, December 11th. Cormark analyst J. Fenwick forecasts that the company will earn $0.00 per share for the quarter. The consensus estimate for Westaim’s current full-year earnings is $0.09 per share. Cormark also issued estimates for Westaim’s Q2 2025 earnings at ($0.01) EPS, Q3 2025 earnings at ($0.01) EPS, Q4 2025 earnings at $0.00 EPS, Q1 2026 earnings at ($0.01) EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.01 EPS, FY2026 earnings at $0.04 EPS and FY2027 earnings at $0.37 EPS.
Westaim Stock Performance
Shares of Westaim stock opened at C$5.13 on Friday. Westaim has a 12 month low of C$3.38 and a 12 month high of C$5.25. The business has a 50-day moving average of C$4.89 and a 200 day moving average of C$4.32. The company has a debt-to-equity ratio of 0.01, a current ratio of 11.67 and a quick ratio of 27.60. The stock has a market capitalization of C$657.51 million, a price-to-earnings ratio of 7.89 and a beta of 0.39.
About Westaim
The Westaim Corporation is a private equity firm specializing in direct and indirect investments through acquisitions, joint ventures, secondary investments both direct and indirect, fund of fund investments, and other arrangements. For direct investments, the firm invests in early venture, mid venture, late venture, middle market, later stage, mature, emerging growth, PIPEs, and buyout transactions.
Recommended Stories
- Five stocks we like better than Westaim
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- 5 discounted opportunities for dividend growth investors
- Texas Instruments: The Old-School Tech Titan Still Delivering
- 3 Stocks to Consider Buying in October
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for Westaim Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Westaim and related companies with MarketBeat.com's FREE daily email newsletter.